10102905Development of a first-in-class bispecific ADC targeting Ovarian CancerClosedCollaborative R&DInnovate UKBiVictriX Therapeutics plc is a UK-based drug-development company focused on developing a novel class of precision oncology therapeutics with greater efficacy and a substantially improved safety profile to benefit patients, their families as well as the healthcare system. Current cancer therapy still exhibits significant and at times severe side effects that can lead to treatment cessation and -- in some cases -- death of the patient due to treatment-related-adverse-effects (TRAEs). Even for precision and targeted treatment options such as antibody-drug conjugates (ADCs) used by clinicians today to treat the most advanced cancer cases, almost half (\>46%) of patients receiving those drugs experience significant to severe toxicities. These affect patients' quality of life as well as their treatment outcome. Through applying a novel approach to precision medicine discovery, BiVictriX is able to generate a new class of oncology therapies that are highly specific for the cancer whilst possessing a significantly improved toxicity profile. BiVictriX discovers and develops bispecific ADCs that bind to two cell-surface proteins on cancer cells; those targets together are not expressed anywhere else within the human body. This in turn ensures delivery of the highly toxic payload (as is used in antibody-drug-conjugated or ADCs) only to cancer cells resulting in their destruction, rather than exhibiting the same fate also to healthy cells. BiVictriX has identified a panel of novel cancer-specific fingerprints across a range of cancer types which represent key unmet needs. Preclinical data of BiVictriX's lead candidate in Acute Myeloid Leukaemia (AML) using this novel bispecific ADC targeting approach are very encouraging, demonstrating significantly an improved safety and efficacy profile versus clinical competitors. A clinical lead has been selected for this program and is being progressed towards human trials in the UK. Applying the same rationale of cancer-specific target pair discovery, BiVictriX has identified a further very promising cancer-specific fingerprint. This target pair is found in a large proportion of patients with high-risk Ovarian Cancer (OC) with survival rates of only 18-45% of patients living for 5 years post diagnosis. BiVictriX has generated initial encouraging data with a proof-of-concept drug candidate in this disease setting using this novel cancer-specific target pair. Through working with Innovate UK, BiVictriX aims to enable and accelerate pre-clinical development of this promising target pair in OC with the aim of progressing the therapeutic into human trials and seeking approval for use of the drug in the UK and worldwide.